Chimeric antigen receptor (CAR)-modified T cell therapy is a rapidly emerging
immunotherapeutic approach that is revolutionizing cancer treatment. The impressive …

Despite many recent advances on cancer novel therapies, researchers have yet a long way
to cure cancer. They have to deal with tough challenges before they can reach success …

Based on the pivotal KarMMa-1 and CARTITUDE-1 studies, Idecabtagene vicleucel (Ide-cel)
and Ciltacabtagene autoleucel (Cilta-cel) have been approved to treat multiple myeloma …

Chimeric antigen receptor T (CAR-T) cell therapy has been a milestone breakthrough in the
treatment of hematological malignancies, offering an effective therapeutic option for multi …

Multiple myeloma remains an incurable disease despite great advances in its therapeutic
landscape. Increasing evidence supports the belief that immune dysfunction plays an …

The signaling lymphocytic activation molecule (SLAM) family participates in the modulation
of various innate and adaptive immune responses. SLAM family (SLAMF) receptors include …

Simple Summary CD229 is a cell-surface molecule predominantly expressed on
lymphocytes. Its expression in B-cell malignancies is poorly known. We tested the presence …

Despite the significant progress of modern anticancer therapies, multiple myeloma (MM) is
still incurable for the majority of patients. Following almost three decades of development …

Introduction As we have just stepped into a new decade of hopes, the mountain of
knowledge learned from multiple myeloma (MM) remains unmatched among cancers. In the …

Cancer remains the primary cause of premature death in the world. Hematological
malignancies collectively account for 1.27 million of those cases, of which the large majority …